About SkinJect
Skinject, Inc. is developing a novel drug delivery system for the treatment of non-melanoma skin cancers.
The system comprises a dissolvable microneedle array (MNA) to deliver a drug directly into the top layer of skin. The drug will kill non-melanoma skin cancer by causing an immune system reaction to combat the disease.
SkinJect consists of three key components:
- Dissolvable microneedles that penetrate the skin, dissolve and deliver the “cargo” − the drug.
- A cellulose-like material that forms the microneedles and carries the cargo. It is FDA-approved for human use.
- A chemotherapy cargo that kills cells and also stimulates an immunological response from the patient’s lesion. Also FDA-approved for human use.
|
|
|
1-10 employees
View all SkinJect employees
|
|
Pharmaceutical Manufacturing
|
|
None
|
|
Basal Cell Carcinoma And Squamous Cell Carcinoma
|
SkinJect Alternatives
SkinJect Staff Directory
Search SkinJect Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.
